Apply to Lenvima (lenvatinib) Copay Assistance Program |QuickRx

Yes, completely free. QuickRx Specialty Pharmacy provides free enrollment support for all Lenvima (lenvatinib) copay assistance programs. We never charge application fees, service charges, or hidden costs—our mission is to help cancer patients access affordable treatment.

What’s included at no cost:

• Complete application assistance for Lenvima copay cards and financial aid programs
• Insurance benefit verification and coverage analysis
• Prior authorization coordination when required
• Continuous benefit monitoring to maintain your savings
• Home delivery coordination and prescription management

Lenvima savings programs available:

For commercially insured patients: Manufacturer copay cards can dramatically reduce your Lenvima prescription costs, often lowering copays to minimal amounts.

For Medicare and Medicaid patients: Independent foundation grant programs offer financial assistance to help cover Lenvima medication expenses.

For uninsured or underinsured patients: Patient assistance programs may provide Lenvima at no cost or significantly reduced prices based on household income and medical necessity.

Contact us at (917) 830-2525 to learn more about your options.

Eligibility for Lenvima (lenvatinib) copay assistance depends on your insurance type, cancer diagnosis, and financial circumstances. Here’s how QuickRx makes enrollment simple:

Step 1: Reach out to QuickRx

Call (917) 830-2525 or toll-free (800) 496-6111, or complete our confidential online enrollment form.

Step 2: Insurance verification

Our team reviews your coverage details and identifies which Lenvima copay assistance programs you’re eligible for based on your plan type.

Step 3: Application submission

We handle all paperwork for copay cards, patient assistance programs, or foundation grants—you simply provide basic information and consent.

Step 4: Receive approval and savings

Most commercial Lenvima copay cards move quickly once eligibility is confirmed. Patient assistance programs may require additional processing time.

Savings with Lenvima copay cards vary depending on your insurance plan and eligibility.

Commercially insured patients: Manufacturer copay cards may reduce your out-of-pocket costs substantially. Eligible patients may pay as little as $0 per prescription fill.

Medicare/Medicaid patients: Foundation grants can provide meaningful financial relief for eligible cancer patients taking Lenvima.

Uninsured patients: Patient assistance programs may cover the full cost of Lenvima for qualifying individuals.

Every patient’s situation is unique. Contact QuickRx at (917) 830-2525 for a personalized assessment of your Lenvima copay assistance options.

Lenvima copay assistance approval moves quickly once eligibility is confirmed. The timeline depends on the type of program:

Manufacturer copay cards: Typically activate quickly for eligible patients with commercial insurance.

Patient assistance programs: May require additional documentation and processing time based on income verification and medical necessity.

Foundation grants: Availability depends on fund status. QuickRx monitors open enrollment periods and applies on your behalf as soon as grants become available.

QuickRx handles all paperwork and follow-up to ensure your application is processed as quickly as possible.

Yes. While Medicare Part D patients are typically not eligible for manufacturer copay cards, QuickRx helps Medicare patients access alternative Lenvima financial assistance options including:

• Independent foundation grant programs for cancer patients
• State pharmaceutical assistance programs (SPAPs)
• Medicare Extra Help / Low-Income Subsidy (LIS) enrollment
• Charitable organization support for oncology medications

Our team at QuickRx specializes in finding Lenvima copay assistance solutions for Medicare patients with cancer. Call (917) 830-2525 to discuss your options.

QuickRx Specialty Pharmacy helps patients access all available Lenvima savings programs, including manufacturer copay cards that function similarly to coupon programs. While QuickRx does not issue coupons directly, we connect you with every available financial assistance option for Lenvima, including:

• Manufacturer copay card programs (for commercially insured patients)
• Patient assistance programs (for uninsured or underinsured patients)
• Foundation grants and charitable assistance
• Insurance navigation to optimize your prescription coverage

If you’ve been searching for a Lenvima coupon or discount card, contact QuickRx at (917) 830-2525 — we’ll find the best savings option for your situation.

Yes! Patients with commercial (private) insurance are often the best candidates for Lenvima copay card programs. Manufacturer copay cards are specifically designed for commercially insured patients and can significantly lower your out-of-pocket costs for Lenvima.

Even if your insurance plan has a high deductible, high copay tier, or step therapy requirements, QuickRx can help you navigate the process and access Lenvima copay assistance. We also assist with prior authorization and insurance appeals if needed.

Call (917) 830-2525 or fill out our enrollment form to get started.

Lenvima (lenvatinib) is an FDA-approved oral cancer medication classified as a multitargeted tyrosine kinase inhibitor. It was first approved by the FDA on February 13, 2015, and is manufactured by Eisai Inc. Lenvima is FDA-approved for the treatment of:

• Thyroid cancer (differentiated): For locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in adults.
• Hepatocellular carcinoma (liver cancer): First-line treatment of unresectable hepatocellular carcinoma (HCC).
• Renal cell carcinoma (kidney cancer): First-line treatment of advanced renal cell carcinoma (RCC) in combination with pembrolizumab. Also used with everolimus in adults following one prior anti-angiogenic therapy.
• Endometrial carcinoma: Treatment of advanced endometrial carcinoma that is mismatch repair proficient or not microsatellite instability-high, in combination with pembrolizumab, in patients with disease progression following prior systemic therapy.

Lenvima is available only through specialty pharmacies. QuickRx Specialty Pharmacy is licensed in all 50 states and can ship Lenvima directly to your home.

Lenvima (lenvatinib) works by blocking multiple receptor tyrosine kinases involved in tumor growth and blood vessel formation. Specifically, lenvatinib inhibits vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3, as well as fibroblast growth factor (FGF) receptors FGFR1 through FGFR4, platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET.

By inhibiting these receptor tyrosine kinases, Lenvima helps slow cancer progression by reducing tumor blood supply (anti-angiogenic effect) and directly decreasing tumor growth (antiproliferative effect).

When used in combination with everolimus for renal cell carcinoma, the combination has demonstrated increased anti-angiogenic and antitumor activity compared to either drug alone.

Like all cancer medications, Lenvima (lenvatinib) may cause side effects. The most commonly reported side effects (occurring in more than 10% of patients in clinical trials) include:

• High blood pressure (hypertension): Reported in 45% to 73% of patients. Regular blood pressure monitoring is essential.
• Fatigue: Reported in 44% to 67% of patients.
• Diarrhea: Reported in 39% to 67% of patients.
• Decreased appetite: Reported in 34% to 54% of patients.
• Weight loss: Reported in 31% to 51% of patients.
• Nausea and vomiting: Nausea in 20% to 47%; vomiting in 16% to 36%.
• Hand-foot syndrome (palmar-plantar erythrodysesthesia): Reported in 27% to 32%.
• Mouth sores (stomatitis): Reported in 11% to 41%.
• Proteinuria (protein in urine): Reported in 26% to 34%.
• Underactive thyroid (hypothyroidism): Reported in approximately 21%.

Your oncology team will monitor you closely for side effects and may adjust your Lenvima dose if needed. For more information, visit the National Cancer Institute’s side effects guide.

While less common, Lenvima (lenvatinib) can cause serious side effects that require immediate medical attention. These include:

• Cardiac toxicity: Heart failure, cardiomyopathy, ventricular dysfunction, and QT interval prolongation have been reported. Your doctor may monitor your heart with ECG testing.
• Severe hypertension: Uncontrolled high blood pressure can lead to serious cardiovascular events. Blood pressure should be monitored regularly.
• Hemorrhage (bleeding): Serious and fatal bleeding events have occurred, including tumor hemorrhage.
• Hepatotoxicity (liver injury): Serious liver problems, including hepatic failure, have been reported. Liver function tests are required regularly.
• Arterial thromboembolic events: Blood clots, heart attacks, and strokes have been reported in 2% to 5% of patients.
• GI perforation or fistula: Holes or abnormal connections in the digestive tract may occur.
• Kidney problems: Proteinuria and renal impairment require monitoring throughout treatment.

Contact your healthcare provider immediately if you experience unusual bleeding, chest pain, severe headache, confusion, sudden vision changes, or severe abdominal pain while taking Lenvima.

The Lenvima (lenvatinib) dosage depends on the type of cancer being treated. All doses are taken orally, once daily, at the same time each day:

• Thyroid cancer (differentiated): 24 mg once daily
• Hepatocellular carcinoma (liver cancer): 12 mg once daily for patients weighing 60 kg (132 lbs) or more; 8 mg once daily for patients weighing less than 60 kg
• Renal cell carcinoma (with pembrolizumab): 20 mg once daily
• Renal cell carcinoma (with everolimus): 18 mg once daily
• Endometrial carcinoma (with pembrolizumab): 20 mg once daily

Lenvima capsule therapy packs are available in multiple daily dose configurations: 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 18 mg, 20 mg, and 24 mg. Each therapy pack contains a 30-day supply. Your doctor may reduce your dose if you experience certain side effects.

Lenvima (lenvatinib) is taken as oral capsules, once daily, at the same time each day. It may be taken with or without food.

Important administration guidelines:

• Swallow Lenvima capsules whole—do not crush or chew them.
• If you cannot swallow capsules, Lenvima can be prepared as a liquid suspension: place the capsules in a small container with a small amount of liquid, wait 10 minutes for the shell to dissolve, then stir and drink the mixture.
• The prepared suspension can be stored refrigerated for up to 24 hours if needed.
• Lenvima is associated with a moderate to high emetic potential—your doctor may prescribe anti-nausea medication alongside your treatment.

Lenvima should be stored at room temperature, between 68°F and 77°F (20°C to 25°C). QuickRx ships Lenvima with appropriate packaging to maintain proper storage conditions.

Lenvima (lenvatinib) may interact with certain other medications. It is especially important to tell your healthcare provider about all medications you take because:

• QT-prolonging medications: Lenvatinib can prolong the QT interval on your heart’s electrical activity. Taking it with other QT-prolonging medications may increase the risk of heart rhythm problems.
• Blood thinners (anticoagulants): Lenvatinib may increase the effects of warfarin. Close monitoring may be required.
• Blood pressure medications: Since hypertension is a common side effect, your doctor may need to adjust your blood pressure medications during treatment.

Always provide your oncology team with a complete list of all prescription medications, over-the-counter drugs, vitamins, and supplements you are taking before starting Lenvima.

While taking Lenvima (lenvatinib), there are important precautions to follow:

• Surgery and dental procedures: Lenvima should be withheld for at least 1 week before elective surgery or invasive dental procedures. It should not be resumed for at least 2 weeks after major surgery, until adequate wound healing has occurred.
• Pregnancy: Lenvima may cause harm to an unborn baby. Patients who could become pregnant should use effective contraception during treatment and for 30 days after the last dose.
• Breastfeeding: Breastfeeding should be discontinued during Lenvima treatment and for 1 week after the last dose.
• Dental health: Perform preventive dental exams before starting Lenvima and maintain good oral hygiene during treatment, as osteonecrosis of the jaw has been reported.

If you miss a dose of Lenvima (lenvatinib) and it is within 12 hours of your scheduled dose time, take the missed dose as soon as you remember. If it has been more than 12 hours since the missed dose, skip that dose entirely and take your next dose at the regular scheduled time.

Do not take two doses of Lenvima at the same time to make up for a missed dose. If you have questions about missed doses, contact your healthcare provider or call QuickRx at (917) 830-2525.

Lenvima (lenvatinib) requires regular monitoring throughout treatment. Your oncology team will typically order the following tests:

• Blood pressure: Monitored after 1 week, then every 2 weeks for 2 months, then at least monthly thereafter.
• Liver function tests (LFTs): At baseline, every 2 weeks for the first 2 months, then at least monthly.
• Kidney function: Baseline and periodically throughout treatment.
• Thyroid function (TSH): Baseline and monthly during treatment.
• Urine protein (proteinuria): Baseline and periodically (urine dipstick; if 2+, then 24-hour urine collection).
• Electrolytes (including calcium): Baseline and periodically, with calcium checked at least monthly.
• ECG: In select patients with certain heart conditions or those taking QT-prolonging medications.
• Pregnancy status: Verified before starting treatment in patients who could become pregnant.

Regular monitoring is essential for safe Lenvima treatment. Never skip scheduled lab appointments.

The duration of Lenvima (lenvatinib) treatment varies depending on your specific cancer type, treatment response, and overall health. In general, Lenvima is continued until disease progression or unacceptable toxicity, as determined by your oncologist.

Your healthcare provider will monitor your response to treatment through regular lab work, imaging studies, and clinical assessments. Never stop taking Lenvima without first consulting your oncology team.

Yes. Lenvima (lenvatinib) is FDA-approved for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in adults. For this indication, the standard dose is 24 mg taken once daily.

Differentiated thyroid cancer includes papillary and follicular subtypes. Lenvima is specifically indicated for patients whose cancer no longer responds to radioactive iodine treatment and continues to progress.

For more information about thyroid cancer treatment options, visit the National Cancer Institute’s thyroid cancer treatment guide.

Yes. Lenvima (lenvatinib) is FDA-approved as a first-line treatment for unresectable hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The dose is based on body weight: 12 mg once daily for patients weighing 60 kg or more, or 8 mg once daily for patients under 60 kg.

Patients with hepatocellular carcinoma taking Lenvima should be monitored closely for signs of liver problems, including hepatic encephalopathy. Your oncologist will check your liver function tests regularly throughout treatment.

Yes. Lenvima (lenvatinib) is FDA-approved for two kidney cancer indications:

• First-line treatment: Lenvima 20 mg daily in combination with pembrolizumab for advanced renal cell carcinoma (RCC).
• Previously treated: Lenvima 18 mg daily in combination with everolimus for patients who have received one prior anti-angiogenic therapy.

For kidney cancer, Lenvima is always used as part of a combination therapy—not as a standalone treatment. Your oncologist will determine which combination is appropriate based on your treatment history and disease characteristics.

Yes. Lenvima (lenvatinib) is FDA-approved for the treatment of advanced endometrial carcinoma in combination with pembrolizumab. This indication is specifically for patients whose tumors are mismatch repair proficient (pMMR) or not microsatellite instability-high (not MSI-H), who have disease progression following prior systemic therapy, and who are not candidates for curative surgery or radiation.

The standard Lenvima dose for endometrial cancer is 20 mg once daily, taken in combination with pembrolizumab.

Currently, there is no generic version of Lenvima (lenvatinib) available in the United States. Lenvatinib is available only as the brand-name product Lenvima, manufactured by Eisai Inc.

Because there is no generic lenvatinib option at this time, copay assistance and patient savings programs are especially important for making treatment affordable. QuickRx Specialty Pharmacy helps patients access all available Lenvima copay cards, manufacturer programs, and patient assistance to reduce out-of-pocket costs.

If a generic version of lenvatinib becomes available in the future, QuickRx will help patients navigate both brand and generic copay assistance options. Contact us at (917) 830-2525 for the most current information.

Yes. QuickRx Specialty Pharmacy is licensed in all 50 states and ships Lenvima directly to patients’ homes nationwide. Lenvima is classified as a specialty medication that is available only through specialty pharmacies, making home delivery an essential service for cancer patients.

QuickRx provides temperature-controlled packaging to ensure your Lenvima arrives safely, along with ongoing refill coordination and prescription management. Our patient navigators are available to answer questions about your medication and help coordinate your care.

Call (917) 830-2525 or toll-free (800) 496-6111 to get started.

For more information about Lenvima (lenvatinib), the following trusted sources provide detailed, medically reviewed information:

• National Cancer Institute (NCI): Lenvatinib Drug Information
• U.S. Food and Drug Administration (FDA): FDA Drug Approvals Database
• American Cancer Society (ACS): Cancer.org
• Mayo Clinic: MayoClinic.org
• MedlinePlus (NIH): MedlinePlus.gov
• Medicare Coverage: Medicare.gov
• Eisai Patient Access: eisaireimbursement.com

For personalized Lenvima copay assistance, contact QuickRx Specialty Pharmacy at (917) 830-2525 or toll-free at (800) 496-6111.